Indication: Sotorasib (INN) 120 mg is used to treat adult patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) possessing KRAS G12C mutations.

Pharmacology: Sotorasib acts as a small molecule inhibitor targeting KRAS G12C, a mutated form of the KRAS oncogene commonly found in various cancers, including NSCLC. By binding irreversibly to KRAS G12C, sotorasib disrupts its signaling pathways, effectively suppressing tumor growth and proliferation.

Dosage and Administration: The prescribed dosage of sotorasib is 960 mg administered orally once daily.

Interactions: Sotorasib can interact with medications that either act as substrates, inducers, or inhibitors of cytochrome P450 (CYP) enzymes. Patients are advised to disclose all medications they are taking to their healthcare providers to prevent potential interactions.

Side Effects: Common adverse effects associated with sotorasib include diarrhea, nausea, fatigue, musculoskeletal pain, hepatotoxicity, and QT prolongation. Serious side effects may include interstitial lung disease, pneumonitis, and infusion-related reactions.

Precautions and Warnings: Patients undergoing sotorasib treatment should be closely monitored for signs of hepatotoxicity, interstitial lung disease, and QT prolongation. Regular liver function tests and electrocardiogram (ECG) monitoring are recommended, and any respiratory symptoms indicative of interstitial lung disease or pneumonitis should be promptly reported.

Overdose Effects: In the event of an overdose, supportive measures should be initiated. Although specific effects of sotorasib overdose are not extensively documented, management should primarily focus on addressing symptoms and providing supportive care.